This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

June 14-16, 2022
Intercontinental Mark Hopkins HotelSan Francisco, California

Siler Panowski
Director of Biology, Solid Tumors at Allogene, USA


Dr. Siler Panowski is a director of biology and the head of the solid tumor department at Allogene Therapeutics. He is directly involved in all aspects of the solid tumor portfolio, including strategy, preclinical development, and IND filings, and is the research lead for Allogene’s clinical candidate, ALLO-316. Additionally, Dr. Panowski’s group focuses on modifications to overcome the solid tumor microenvironment, including discovery and development of Allogene’s TurboCAR technology. Dr. Panowski has over twelve years of industry experience targeting solid tumors, including work on ADCs, CD3 bispecifics, and CAR T at Pfizer and Genentech.

Agenda Sessions

  • Preclinical CAR T Discovery Candidate Selection for Targets such as CD70 Or DLL3

  • Speaker Q&A